HPLC-based activity profiling of anti-hepatocellular carcinoma constituents from the Tibetan medicine, Caragana tibetica.
10.1007/s11596-015-1452-z
- Author:
Ping SONG
1
;
Qiang WANG
;
Jing-Nan LV
;
Chan XU
;
Qin-Xiong LIN
;
Xin-Hua MA
;
Mi HUANG
;
Xin-Zhou YANG
Author Information
1. College of Chemistry and Life Sciences, Qinghai University for Nationalities, Xining, 810007, China, spzhe@126.com.
- Publication Type:Journal Article
- MeSH:
Acetates;
pharmacology;
Antineoplastic Agents;
chemistry;
pharmacology;
Caragana;
chemistry;
Carcinoma, Hepatocellular;
drug therapy;
Cell Line, Tumor;
Chalcones;
pharmacology;
Chromatography, High Pressure Liquid;
Hep G2 Cells;
Humans;
Liver Neoplasms;
drug therapy;
Medicine, Tibetan Traditional;
Plant Extracts;
chemistry;
pharmacology;
Plant Roots;
chemistry
- From:
Journal of Huazhong University of Science and Technology (Medical Sciences)
2015;35(3):450-455
- CountryChina
- Language:English
-
Abstract:
During the screening of a traditional Chinese folk herb library against HepG2 and Hep3B cell lines, the EtOAc extract from the Tibetan medicine, Caragana tibetica (CT-EtOAc) exhibited potential anti-hepatocellular carcinoma (anti-HCC) activity. HPLC-based activity profiling was performed for targeted identification of anti-HCC activity from CT-EtOAc by MS-directed purification method. CT-EtOAc was separated by time-based fractionation for further anti-HCC bioassay by a semipreparative HPLC column (150 mm × 10 mm i.d., 5 μm) with a single injection of 5 mg. Bioassay-guided and ESIMS-directed large scale purification was performed with a single injection of 400 mg of CT-EtOAc by peak-based fractionation. A 1.4-mm heavy wall micro NMR tube with z-gradient was used to measure one and two dimensional NMR spectra for the minor or trace amounts of components of the extract. Two active compounds could be elucidated as naringenin chalcone (CT-1) and 3-hydroxy-8, 9-dimethoxypterocarpan (CT-2) relevant to anti-HCC effects for the EtOAc extract of C. tibetica rapidly and unambiguously by this protocol.
